NOVATO, Calif., Sept. 11 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Joshua Grass, Vice President of Business and Corporate Development of BioMarin, will present a company update at the Merrill Lynch Global Pharmaceutical Conference in London on Thursday, September 18, 2008 at 10:35 a.m. BST.
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, http://www.BMRN.com. A replay of the call will be archived on the site for one week following the call.
BioMarin develops and commercializes innovative biopharmaceuticals for
serious diseases and medical conditions. The company's product portfolio
comprises three approved products and multiple clinical and preclinical
product candidates. Approved products include Naglazyme(R) (galsulfase) for
mucopolysaccharidosis VI (MPS VI), a product wholly developed and
commercialized by BioMarin; Aldurazyme(R) (laronidase) for
mucopolysaccharidosis I (MPS I), a product which BioMarin developed through
a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin
dihydrochloride) Tablets, a product for the treatment of phenylketonuria
(PKU), developed in partnership with Merck Serono, a division of Merck KGaA
of Darmstadt, Germany. Other product candidates include 6R-BH4 for
cardiovascular indications, which is currently in Phase 2 clinical
development for the treatment of peripheral arterial disease and sickle
cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia
lyase), which is currently in Phase 1 clinical development for the
treatment of PKU. For additional information, please vi
|SOURCE BioMarin Pharmaceutical Inc.|
Copyright©2008 PR Newswire.
All rights reserved